VistaGen Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: South San Francisco CA United States (1998)

Organization Overview

First Clinical Trial
2011
NCT01483846
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

VistaGen Therapeutics | VistaGen Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: VistaGen Therapeutics, Inc. (0) Acquired (2)

ph80 (1 trial)

ph94b (6 trials)

Drugs in Phase 2 Trials (2)

av-101 (3 trials)

l-4-cl-kyn (2 trials)

Drugs in Phase 1 Trials (1)

probenecid (colbenemid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adjustment Disorders (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Dyskinesia, Drug-Induced (Phase 2)

Dyskinesias (Phase 2)

Neuralgia (Phase 1)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 5